Antitope to humanise asthma antibody in deal with NKT Therapeutics

Collaboration

Antitope Ltd has announced a research agreement with NKT Therapeutics to apply its Composite Human Antibody technology for the generation of humanised antibodies for treatment of asthma and other chronic diseases.

“This partnership utilises Antitope's expertise in engineering humanised antibodies devoid of T cell epitopes and complement NKT's innovation in developing novel therapeutics based on monoclonal antibodies targeting Natural Killer T cells,” said Matthew Baker, Chief Scientific Officer and co-founder of Cambridge-based Antitope. "We are delighted to be working with NKT who we recognise as leaders in the biology and therapeutic applications of modulating Natural Killer T cells.”